Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) have earned a consensus recommendation of “Moderate ...

Full-year 2024 ORLADEYO revenue guidance adjusted to $430-$435 million (top end of prior guidance range) — — Company ...

BioCryst Pharmaceuticals (NASDAQ: BCRX) Q3 2024 Earnings Call Nov 04, 2024, 8:30 a.m. ET Good day and Welcome to the BioCryst ...

A Durham company says its drug is pacing for over $400 million in revenue this year. The goal is $1 billion.

Q3 2024 Earnings Call Transcript November 4, 2024 Operator: Good day and Welcome to the BioCryst Third Quarter 2024 Earnings ...

Begin your TipRanks Premium journey today. BioCryst (BCRX) Company Description: BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes ...

BioCryst Pharmaceuticals ( (BCRX) ) has released its Q3 earnings. Here is a breakdown of the information BioCryst Pharmaceuticals presented to ...

RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced ...

The drugmaker posted revenue of $117.1 million in the period, surpassing Street forecasts. Three analysts surveyed by Zacks expected $114.8 million. BioCryst expects full-year revenue in the range of ...

JP Morgan has recently resumed BioCryst Pharmaceuticals Inc (BCRX) stock to Overweight rating, as announced on November 20, 2023, according to Finviz. Earlier, on September 18, 2023, RBC Capital Mkts ...